Prana publishes research on preclinical AD treatment

Prana Biotechnology has published preclinical research into its lead Alzheimer's disease drug, PBT2. The article, titled Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-hydroxyquinoline Analogs is Associated with Decreased Interstitial Amyloid Beta Protein (Abeta), appears in the current edition of the scientific journal Neuron, and can be viewed on-line.

The report's key findings include that PBT2: profoundly and rapidly improved cognition in transgenic mice; prevented the formation of soluble Abeta oligomers, the form of Abeta believed to be the most toxic; substantially reduced the amount of all forms of Abeta in the transgenic mouse brain, over a nine-week period; significantly lowered soluble (interstitial) Abeta in the brain, sampled using in vivo microdialysis, within hours of oral administration; and protected neurons in living brain tissue from the toxic effects of Abeta which impairs the signaling between neurons in Alzheimer's disease.

The data will be presented at the 11th International Conference on Alzheimer's Disease in Chicago, USA, on July 29.